Effective long-term management of MS disease.
 

StellarQ MS

MS has been developed in collaboration with leading neurologists in Finland. The service enables real-time comparison of decision-making and effectiveness of patient care. Implementation of the core parameters with all units responsible for patient care improves utilization of best practice, equal and high quality treatment for the benefit of the patient. StellarQ MS has approved and certificated with CE mark.    

MS has been designed to be user-friendly for physicians and nurses by analyzing the key processes related to the treatment situation. An overall picture of the patient’s situation can be quickly formed, as the key information for the treatment is compiled into illustrative summary views. The information is saved as clear and structural elements, each of which also includes a summary of all past events.

stellarq-ms-blue.png

The service can be integrated with the existing key systems of the hospital, by customizing API's to suite the client's needs. Structured data from MS can be transferred and utilized in the existing EHR system, therefore streamlining the processes and reducing extra administrative burden.

 

Novel immunomodulatory treatments require intermittent monitoring of key laboratory markers. MS laboratory interface integrates with hospital's laboratory system which makes them readily available and provides effective alarm functionality.

Quantitative neuroradiological imaging has become increasingly important in patient follow up. MS neuroradiological interface integrates with the hospital's imaging system making the process effortless and analyzable.

For example, in collaboration with us, the Finnish Neuroradiological Association developed a neuroradiological atlas for the imaging protocol and quantification of neuroradiological findings into a structured database. 

 

How does ms motivate physicians and nurses?

When physicians and nurses at a clinic commit themselves to using MS, they get access to a tool that concentrates the essential information, thus facilitating their everyday work.

In addition to fixed work stations, the system supports mobile devices and touchscreens. The system allows health care professionals to follow the condition of their own patients and thus receive feedback on their own performance. The professionals committed to the services do not just promote the well-being of MS patients at their own clinics; sharing the national anonymous summarized information improves the quality of all units responsible for the treatment of MS patients.

National comparative information plays an important role in the decision-making at a clinic when the decisions on resources are based on actual information produced together.

ce-mark.png

 

 

StellarQ My MS

Online health care services and patient engagement channels are getting more popular in Europe. My MS provides the patients with a user-friendly and graphically illustrative user interface for reporting and managing the events in his or hers own disease. The health care unit gets notifications about recent changes in the patient's disease, which allows for planning further measures ahead of meeting the patient.  

The service gives the patient a real-time overall picture and a history view to his or hers own disease. Communication between the doctor and patient improves when the doctor can get an up-to-date view of the recent changes in the patient's life. In sparsely populated areas the service facilitates communication between a patient and the health care unit.

stellarq-myms-logo-pos.png

Patient reported data is utilized together with clinical data. Time is saved when the nurse and doctor know the full history and recent changes in the disease.

 
myms_laptop.png
 
Recording and management of patients’ own health information promote co-operation with the care unit.
 

My MS is an effective Patient Reported Outcome (PRO) tool for healthcare decision makers and pharmaceutical industry

Information on a patient’s experience of their disease, condition or treatment that is sourced directly from the patient may come in a variety of forms, of which patient‑reported outcome (PRO) measures are one of the most topical and highly rated in the pharmaceutical industry today. Patient reported outcome is any report of the status of a patient’s health condition that comes directly from the patient, without interpretation of the patient’s response by a clinician or anyone .

PRO measures are growing in importance as pharma generally leans more towards patient centricity as the common denominator across many of its functions. How the symptoms of the disease are changing, as well as how the adverse events of the therapy are impacting them. There is increasing emphasis on asking the patient more about the tolerability of the drugs that they are taking (FirstWord Dossier; Patient Reported Outcomes, Strategies for gaining or expanding market access, May 2016).

 

 

StellarQ Spark

Existing hospital patient records are descriptive and fragmented in nature. This makes the fast and precise evaluation of the clinical situation challenging.

According to detail service concept, the primary and secondary diagnoses as well as co-morbidities can be comprehensively determined using data-mining and analytical methods.

We utilize specialised personnel educated to import existing data. Therefore, all commonly determined core parameters can be obtained. The service also incorporates process management and all necessary approvals and documentation.

 

 

 

StellarQ Cohort produces reliable research data on treatment decisions for healthcare units, and helps pharmaceutical companies to identify the treatment chains, and the content of treatments, in a specific area.

StellarQ Cohort

StellarQ Cohort service is always implemented on the basis of the customer’s needs. The research service can be utilised by pharmaceutical companies or public sector units that need the latest information to support their decision-making. The service can be used to examine anonymously the treatment received by a patient suffering from a specific disease at different treatment levels or the prevalence of a certain disease in different parts of the treatment chain. The research can be performed either as a one-off cross-section study or as a repeated follow-up study.

The customer will receive the service as an overall delivery, including the production of research material, management of the permit process, researcher recruitment, analysing of research data, research report, and writing of an article.

Pharmaceutical companies need fresh information on patient care, for which e.g. the methods of register research are not sufficiently up-to-date and precise. The SQ Cohort service will include those treatment levels and health care professionals that are in a decisive role in accordance with the research setting when decisions on the treatment are made. The treatment unit and health care professionals undertake to produce research data, because they will also benefit from the service by receiving real-time information on their own treatment decisions and national anonymous comparative information from their own area of specialisation.

 

Case: ATTAC

The study examined the prevalence of peripheral coronary artery disease in persons with high risk for arteriosclerosis (age 50–69 and at least one risk factor of cardiovascular diseases or age >70 or pain in calves when walking) who came to the health centre for any reason. The peripheral coronary artery disease was diagnosed using the ankle brachial index. On the basis of the results it was possible to estimate the prevalence of peripheral coronary artery disease in basic health care.

Around 100 physicians in basic health care with national coverage participated in the data collection service for the ATTAC study. Efficient data collection using a browser allowed for implementation of the study over a period of a few months. The SQ Cohort services offers real-time data collection follow-up and quality control, as a result of which the studies can be implemented quickly and cost-efficiently.